Market revenue in 2023 | USD 258.5 million |
Market revenue in 2030 | USD 536.1 million |
Growth rate | 11% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.69% in 2023. Horizon Databook has segmented the Latin America circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Latin America branded generic market is anticipated to witness significant growth over the forecast period owing to rising prevalence of chronic diseases and conditions associated with geriatric & obese population coupled with increasing prescription trend of generic products in the region.
Furthermore, increasing government initiatives, such as patient awareness campaigns; investments in the healthcare sector; and the need to reduce healthcare expenditure may contribute to market growth in the region. In the biosimilar market in Latin America it was found that Brazil, Mexico, and Argentina have the largest number of approved Similar Biotherapeutic Products (SBPs) as of 2020.
Investments from pharmaceutical companies are increasing in the region. Government initiatives for cost containment in countries such as Colombia have created opportunity for generic drug companies. The shift in global focus from Brazil to other Latin American nations for API supply is another factor contributing to the overall growth of the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America circulating tumor cells market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account